Establishment of H₂Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer

Shinji Yamada,1 Shunsuke Itai,1,2 Takuro Nakamura,1 Yao-Wen Chang,1 Hiroyuki Harada,2 Hiroyoshi Suzuki,3 Mika K. Kaneko,1 and Yukinari Kato1,4

Establishment of H₂Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer

Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast cancer and is associated with poor clinical outcomes. In addition, HER2 expression has been reported in other cancers, such as gastric, colorectal, lung, and pancreatic cancers. An anti-HER2 humanized antibody, trastuzumab, leads to significant survival benefits in patients with HER2-overexpressing breast cancers and gastric cancers. Herein, we established a novel anti-HER2 monoclonal antibody (mAb), H₂Mab-119 (IgG1, kappa), and characterized its efficacy against pancreatic cancers using flow cytometry, Western blot, and immunohistochemical analyses. H₂Mab-119 reacted with pancreatic cancer cell lines, such as KLM-1, Capan-2, and MIA PaCa-2, but did not react with PANC-1 in flow cytometry analysis. Western blot analysis also revealed a moderate signal for KLM-1 and a weak signal for MIA PaCa-2, although H₂Mab-119 reacted strongly with LN229/HER2 cells. Finally, immunohistochemical analyses with H₂Mab-119 revealed sensitive and specific reactions against breast and colon cancers but did not react with pancreatic cancers, indicating that H₂Mab-119 is useful for detecting HER2 overexpression in pancreatic cancers using flow cytometry and Western blot analyses.

Keywords: HER2, monoclonal antibody, immunohistochemistry, pancreatic cancer

Introduction

HER2 overexpression is reported in >20% of patients with breast cancer and is associated with poor clinical outcomes. Humanized anti-HER2 monoclonal antibodies (mAbs), such as trastuzumab and pertuzumab; antibody-drug conjugate, including trastuzumab emtansine; and tyrosine kinase inhibitors, such as lapatinib, have been approved for the treatment of HER2-positive breast cancers. Trastuzumab treatments have resulted in significant survival benefits in patients with metastatic HER2-positive breast cancers. Furthermore, the combination of pertuzumab and trastuzumab in chemotherapy has led to significant improvements in overall survival compared with trastuzumab alone plus chemotherapy. In addition, overexpression of HER2 has been reported in gastric cancers, colorectal cancers, lung cancers, and pancreatic cancers. In this study, we developed a novel anti-HER2 mAb and investigated its utility using flow cytometry, Western blot, and immunohistochemical analyses for pancreatic cancers.

Materials and Methods

Cell lines, tissues, and animals

LN229, Capan-2, and P3U1 cell lines were obtained from the American Type Culture Collection (Manassas, VA). KLM-1, PANC-1, and MIA PaCa-2 cell lines were obtained from the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer Tohoku University (Miyagi, Japan). LN229/HER2 was produced by transfecting pCAG/PA-HER2-RAP-MAP(13) into LN229 cells using the neon transfection system (Thermo Fisher Scientific, Inc., Waltham, MA). A few days after transfection, PA tag-positive cells(14) were sorted using a cell sorter (SH800; Sony Corp., Tokyo, Japan). P3U1, KLM-1, and PANC-1 cell lines were cultured in RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto,

1Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
2Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
3Department of Pathology and Laboratory Medicine, Sendai Medical Center, Sendai, Japan.
4New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.

287
underwent surgery at Sendai Medical Center was used for this study. The Animal Care and Use Committee of Tohoku University approved all the animal experiments described in this study. The mice were housed under specific pathogen-free conditions. Female 4-week-old BALB/c mice were purchased from CLEA Japan (Tokyo, Japan). An equally, H2Mab-119), anti-MAP tag (1:1000; Cell Signaling Technology, Inc.), and anti-β-actin (1 μg/mL, clone AC-15; Sigma-Aldrich Corp., St. Louis, MO) and then with peroxidase-conjugated antimouse IgG or antirat IgG (1:1000 diluted; Agilent Technologies, Inc., Santa Clara, CA). Finally, membranes were developed using ImmunoStar LD (Wako Pure Chemical Industries Ltd.) with a Sayaca-Imager (DRC Co. Ltd., Tokyo, Japan).

**Immunohistochemical analyses**

Histological sections of 4 μm thickness were deparaffinized in xylene and subsequently rehydrated and autoclaved in EnVision FLEX Target Retrieval Solution, high pH (Agilent Technologies, Inc.), for 20 minutes. Sections were then incubated with 10 μg/mL of H2Mab-119 for 1 hour at room temperature and treated using an Envision+ kit (Agilent Technologies, Inc.) for 30 minutes. Color was developed using 3,3-diaminobenzidine tetrahydrochloride (Agilent Technologies, Inc.) for 2 minutes; subsequently, sections were counterstained with hematoxylin (Wako Pure Chemical Industries Ltd.).

**Results and Discussion**

In this study, we immunized mice with purified recombinant extracellular domain of HER2. Culture supernatants were then screened using ELISA. We used flow cytometry analyses to assess reactions with LN229 and LN229/HER2 cells. A stronger reaction against LN229/HER2 was necessary because LN229 cells express endogenous HER2. We obtained one clone H2Mab-119 (IgG1, kappa).

In flow cytometric analyses, H2Mab-119 reacted with LN229/HER2 more strongly than with endogenous HER2-expressing LN229 glioblastoma cells (Fig. 1A). H2Mab-119 also reacted with CHO/HER2 but did not react with the parental cell strain CHO-K1 (data not shown), indicating that H2Mab-119 is specific for HER2. H2Mab-119 recognized endogenous HER2 in pancreatic cancer cell lines, such as KLM-1, Capan-2, and MIA PaCa-2, but did not react with PANC-1 (Fig. 1B). In Western blots against LN229 and LN229/HER2 as well as pancreatic cancer cell lines, H2Mab-119 detected a 180–200 kDa protein in LN229/HER2 (Fig. 1C). In contrast, H2Mab-119 detected a moderate signal in KLM-1, a weak signal in MIA PaCa-2, and a faint signal in both PANC-1 and Capan-2, indicating that H2Mab-119 is useful for Western blot analysis of pancreatic cancer cell lines.

Finally, we investigated the immunohistochemical utility of H2Mab-119 in human breast cancers and pancreatic cancers. As shown in Figure 1D, H2Mab-119 stained the cancer cell membranes of breast cancers and colon cancers that were diagnosed previously as HER2-positive breast cancer. In contrast, H2Mab-119 did not stain HER2-positive pancreatic cancer tissues (data not shown), indicating that H2Mab-119 is applicable only for flow cytometry and Western blot analyses against pancreatic cancers in this study, although it is useful for immunohistochemical analysis against breast cancers and colon cancers. In the future, we should stain many pancreatic cancer tissues to determine the positive rate in immunohistochemistry using H2Mab-119.

**Acknowledgments**

We thank Miyuki Yanaka, Noriko Saidoh, Saori Handa, Yoshimi Nakamura, Yoshikazu Satoh, and Maki Takahashi for their assistance in conducting the experiments.
for excellent technical assistance. This work was supported, in part, by the Basic Science and Platform Technology Program for Innovative Biological Medicine from Japan Agency for Medical Research and Development, AMED (Y.K.), by Project for utilizing glycans in the development of innovative drug discovery technologies from AMED (Y.K.), and by Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research, BINDS) from AMED.

FIG. 1. Characterization of H2Mab-119. (A, B) Flow cytometry with H2Mab-119; cells were treated with 10 μg/mL of H2Mab-119, followed by Alexa Fluor 488-conjugated anti-mouse IgG; black line, negative control. (C) Western blotting using H2Mab-119; cell lysates were electrophoresed and proteins were transferred onto PVDF membranes. After blocking, membranes were incubated with 10 μg/mL of H2Mab-119, 1 μg/mL of anti-MAP tag (PMab-1), or 1 μg/mL of anti-β-actin (AC-15) and subsequently incubated with peroxidase-conjugated antimouse IgG against H2Mab-119 and AC-15 or antirat IgG against PMab-1. (D) Sections were incubated with 10 μg/mL of H2Mab-119 for 1 hour at room temperature, followed by treatment with Envision+ kit for 30 minutes. Color was developed using 3,3-diaminobenzidine tetrahydrochloride for 2 minutes; subsequently, sections were counterstained with hematoxylin. Scale bar = 100 μm.
Author Disclosure Statement

Y.K. received research funding from Ono Pharmaceutical Co., Ltd. All other authors have nothing to disclose.

References


9. Xie S, Zhang H, Wang X, Ge Q, and Hu J: The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated ad-


Address correspondence to:

Yukinari Kato
New Industry Creation Hatchery Center
Tohoku University
Department of Antibody Drug Development
Tohoku University Graduate School of Medicine
2-1 Seiryo-machi
Aoba-ku
Sendai
Miyagi 980-8575
Japan

E-mail: yuki nari-k@bea.hi-ho.ne.jp;
yukinarikato@med.tohoku.ac.jp

Received: September 15, 2017
Accepted: October 30, 2017